In Brief: Glaxo Wellcome Ceftin tablets
Glaxo Wellcome Ceftin tablets: Antibiotic cefuroxime is cleared March 11 for additional indication of acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae and non-beta-lactamase-producing strains of Haemophilus influenzae. Recommended dose is 250 mg twice daily for 10 days, the same dose recommended for other respiratory infections. Ceftin tablets also are indicated in the treatment of pharyngitis/tonsillitis, otitis media, bronchitis, skin and skin structure infections, urinary tract infections and gonorrhea...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth